TY - JOUR
T1 - Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention
AU - Mangiacapra, Fabio
AU - Sticchi, Alessandro
AU - Bressi, Edoardo
AU - Mangiacapra, Roberto
AU - Viscusi, Michele Mattia
AU - Colaiori, Iginio
AU - Ricottini, Elisabetta
AU - Cavallari, Ilaria
AU - Spoto, Silvia
AU - Ussia, Gian Paolo
AU - Ferraro, Pietro Manuel
AU - Grigioni, Francesco
PY - 2021
Y1 - 2021
N2 - We investigated the interaction between chronic kidney disease (CKD) and high platelet reactivity (HPR) in determining long-term clinical outcomes following elective PCI for stable coronary artery disease (CAD). A total of 500 patients treated with aspirin and clopidogrel were divided based on the presence of CKD (defined as glomerular filtration rate of < 60 ml/min/1.73 m2) and HPR (defined as a P2Y12 reaction unit value ≥ 240 at VerifyNow assay). Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both CKD and HPR showed the highest estimates of MACE (25.6%, p = 0.005), all-cause death (17.9%, p = 0.004), and cardiac death (7.7%, p = 0.004). The combination of CKD and HPR was an independent predictor of MACE (HR 3.12, 95% CI 1.46–6.68, p = 0.003). In conclusion, the combination of CKD and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.
AB - We investigated the interaction between chronic kidney disease (CKD) and high platelet reactivity (HPR) in determining long-term clinical outcomes following elective PCI for stable coronary artery disease (CAD). A total of 500 patients treated with aspirin and clopidogrel were divided based on the presence of CKD (defined as glomerular filtration rate of < 60 ml/min/1.73 m2) and HPR (defined as a P2Y12 reaction unit value ≥ 240 at VerifyNow assay). Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both CKD and HPR showed the highest estimates of MACE (25.6%, p = 0.005), all-cause death (17.9%, p = 0.004), and cardiac death (7.7%, p = 0.004). The combination of CKD and HPR was an independent predictor of MACE (HR 3.12, 95% CI 1.46–6.68, p = 0.003). In conclusion, the combination of CKD and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.
KW - Chronic kidney disease
KW - Coronary artery disease
KW - Percutaneous coronary intervention
KW - Platelet reactivity
KW - Chronic kidney disease
KW - Coronary artery disease
KW - Percutaneous coronary intervention
KW - Platelet reactivity
UR - http://hdl.handle.net/10807/181306
U2 - 10.1007/s12265-021-10126-8
DO - 10.1007/s12265-021-10126-8
M3 - Article
SN - 1937-5387
SP - N/A-N/A
JO - Journal of Cardiovascular Translational Research
JF - Journal of Cardiovascular Translational Research
ER -